Similar content being viewed by others
References
Després JP and Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444: 881–887
Hamdy O et al. (2006) Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev 2: 367–373
Ritchie SA and Connell JM (2007) The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 17: 319–326
Guilherme A et al. (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9: 367–377
Di Marzo V (2008) The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 51: 1356–1367
Matias I et al. (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 3171–3180
Pagano C et al. (2007) The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 92: 4810–4819
Blüher M et al. (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55: 3053–3060
Côté M et al. (2007) Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 31: 692–699
Aronne LJ and Isoldi KK (2007) Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy. Am J Cardiol 100: 18P–26P
Van Gaal L et al. (2008) Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 (Suppl 2): S229–S240
Nissen SE et al. for the STRADIVARIUS Investigators (2008) Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299: 1547–1560
Sanofi Aventis (online 5 May 2008) Imaging results from the ADAGIO-Lipids reveal that effects of rimonabant on cardiometabolic risk profile include loss of visceral fat and mobilization of liver fat. [http://www.sanofi-aventis.se/live/se/sv/layout.jsp?cnt=52DC240C-CD09- 4B62-87DC-C3FDD0B8AA43] (accessed 3 July 2008)
Osei-Hyiaman D et al. (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115: 1298–1305
Di Marzo V (2008) Targeting the endocannabinoid system: to enhance or reduce. Nat Rev Drug Discov 7: 438–455
Van Gaal LF et al. (2008) Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J [doi: 10.1093/eurheartj/ehn076]
Author information
Authors and Affiliations
Ethics declarations
Competing interests
V Di Marzo has received research support and Speakers' Bureau honoraria from Sanofi-Aventis.
Rights and permissions
About this article
Cite this article
Di Marzo, V. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?. Nat Rev Cardiol 5, 610–612 (2008). https://doi.org/10.1038/ncpcardio1319
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio1319
- Springer Nature Limited
This article is cited by
-
The Endocannabinoid System: Potential for Reducing Cardiometabolic Risk
Obesity (2009)
-
The emerging role of the endocannabinoid system in cardiovascular disease
Seminars in Immunopathology (2009)